Needham & Company LLC Increases Liquidia (NASDAQ:LQDA) Price Target to $110.00

Liquidia (NASDAQ:LQDA) had its price objective upped by equities research analysts at Needham & Company LLC from $70.00 to $110.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target suggests a potential upside of 39.12% from the company’s current price.

LQDA has been the topic of several other reports. Wells Fargo & Company raised their price objective on shares of Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Stephens set a $130.00 target price on shares of Liquidia in a report on Friday, July 24th. Raymond James Financial reiterated a “strong-buy” rating and set a $68.00 target price on shares of Liquidia in a research note on Thursday, June 4th. Royal Bank Of Canada set a $130.00 price target on Liquidia in a report on Friday, July 24th. Finally, Wall Street Zen cut Liquidia from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $90.00.

Liquidia Stock Performance

Shares of LQDA traded down $8.98 during mid-day trading on Wednesday, reaching $79.07. 3,040,638 shares of the company’s stock were exchanged, compared to its average volume of 1,774,534. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The stock has a market capitalization of $7.03 billion, a PE ratio of 564.83 and a beta of 0.58. The business’s fifty day simple moving average is $77.76 and its 200-day simple moving average is $54.51. Liquidia has a 52-week low of $21.15 and a 52-week high of $93.61.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business had revenue of $171.68 million during the quarter, compared to analyst estimates of $168.48 million. During the same period in the previous year, the firm earned ($0.49) earnings per share. The business’s revenue was up 1842.1% compared to the same quarter last year. On average, equities research analysts expect that Liquidia will post 3.02 earnings per share for the current year.

Insiders Place Their Bets

In other Liquidia news, Director Stephen M. Bloch sold 242,269 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $70.43, for a total value of $17,063,005.67. Following the transaction, the director directly owned 1,176,184 shares of the company’s stock, valued at approximately $82,838,639.12. The trade was a 17.08% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Paul B. Manning sold 200,000 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $63.91, for a total transaction of $12,782,000.00. Following the transaction, the director owned 716,311 shares of the company’s stock, valued at approximately $45,779,436.01. The trade was a 21.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 1,781,861 shares of company stock worth $124,407,112. 25.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in LQDA. TCG Crossover Management LLC acquired a new stake in Liquidia in the third quarter valued at $38,887,000. MPM Bioimpact LLC grew its stake in shares of Liquidia by 600.4% during the 4th quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after purchasing an additional 1,200,869 shares during the period. Voloridge Investment Management LLC purchased a new position in shares of Liquidia in the 3rd quarter valued at about $12,571,000. Bank of New York Mellon Corp purchased a new position in shares of Liquidia in the 2nd quarter valued at about $29,694,000. Finally, Bank of America Corp DE increased its holdings in shares of Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after purchasing an additional 360,372 shares in the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales accelerated. Net product sales reached approximately $170.4 million in the second quarter, up 31% from the first quarter. Liquidia reported roughly 5,900 unique prescriptions and more than 5,000 patients treated since the product launched in June 2025. Liquidia Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Profitability and cash generation improved. Liquidia posted $171.7 million in revenue, $74.7 million in net income and $96.3 million in adjusted EBITDA, marking its fourth consecutive quarter of increasing profitability. Cash and equivalents rose to approximately $284.2 million from $190.7 million at the end of 2025. Liquidia Q2 Net Income Reaches $74.7 Million As YUTREPIA Sales Rise
• Positive Sentiment: Management maintained its long-term growth outlook. Liquidia reaffirmed its target of more than $1 billion in net revenue in 2027 and is advancing 10 clinical studies involving YUTREPIA and the L606 inhaled treprostinil program.
• Neutral Sentiment: Institutional interest remains mixed but generally supportive. Recent filings showed major investors including BlackRock and State Street adding shares, although some funds reduced their positions.
• Negative Sentiment: Adjusted expectations contributed to the selloff. Diluted EPS of $0.74 was slightly below the approximately $0.76 analyst consensus cited by several reports, despite revenue exceeding expectations. Another estimate source placed consensus at $0.70, highlighting differences among analyst forecasts. Liquidia shares fall after second-quarter earnings miss despite revenue growth
• Negative Sentiment: Spending is increasing. Research and development expenses rose to $17.2 million from $6.0 million a year earlier as Liquidia funds the Phase 3 L606 program. The company’s elevated valuation also leaves less room for disappointing results.
• Negative Sentiment: Insider selling is a potential overhang. Reported insider activity over the past six months consisted overwhelmingly of sales, including transactions by senior executives, with only one reported purchase.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).